Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.04+0.06 (+0.55%)
Close on Nov 17, 2026Market cap $5.40BP/E –Yield –
Gossamer Bio cash
Cash and short-term investments held at the end of each period.
Gossamer Bio's cash was $57.03M at Jun 30, 2026. For fiscal 2025 it was $136.93M, down 53.5% from the year before. The highest annual figure on record is $513.19M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.93M | -53.5% |
| FY2024 | Dec 31, 2024 | $294.52M | -0.6% |
| FY2023 | Dec 31, 2023 | $296.43M | +15.9% |
| FY2022 | Dec 31, 2022 | $255.68M | -21.4% |
| FY2021 | Dec 31, 2021 | $325.28M | -36.6% |
| FY2020 | Dec 31, 2020 | $513.19M | +27.7% |
| FY2019 | Dec 31, 2019 | $401.83M | +75.6% |
| FY2018 | Dec 31, 2018 | $228.86M | +72553.3% |
| FY2017 | Dec 31, 2017 | $315.00K | +425.0% |
| FY2016 | Dec 31, 2016 | $60.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.03M | -73.2% |
| Q1 FY2026 | Mar 31, 2026 | $99.22M | -61.5% |
| Q4 FY2025 | Dec 31, 2025 | $136.93M | -53.5% |
| Q3 FY2025 | Sep 30, 2025 | $180.22M | -44.9% |
| Q2 FY2025 | Jun 30, 2025 | $212.92M | -39.9% |
| Q1 FY2025 | Mar 31, 2025 | $257.93M | +5.5% |
| Q4 FY2024 | Dec 31, 2024 | $294.52M | -0.6% |
| Q3 FY2024 | Sep 30, 2024 | $327.03M | -0.6% |
| Q2 FY2024 | Jun 30, 2024 | $354.49M | +118.6% |
| Q1 FY2024 | Mar 31, 2024 | $244.39M | +21.1% |
| Q4 FY2023 | Dec 31, 2023 | $296.43M | +15.9% |
| Q3 FY2023 | Sep 30, 2023 | $328.89M | +8.1% |
| Q2 FY2023 | Jun 30, 2023 | $162.13M | -27.0% |
| Q1 FY2023 | Mar 31, 2023 | $201.86M | -25.7% |
| Q4 FY2022 | Dec 31, 2022 | $255.68M | -21.4% |
| Q3 FY2022 | Sep 30, 2022 | $304.38M | -16.9% |
| Q2 FY2022 | Jun 30, 2022 | $222.16M | -45.3% |
| Q1 FY2022 | Mar 31, 2022 | $271.69M | -40.1% |
| Q4 FY2021 | Dec 31, 2021 | $325.28M | -36.6% |
| Q3 FY2021 | Sep 30, 2021 | $366.08M | -34.1% |
| Q2 FY2021 | Jun 30, 2021 | $406.49M | -32.3% |
| Q1 FY2021 | Mar 31, 2021 | $453.62M | +31.0% |
| Q4 FY2020 | Dec 31, 2020 | $513.19M | +27.7% |
| Q3 FY2020 | Sep 30, 2020 | $555.38M | +24.4% |
| Q2 FY2020 | Jun 30, 2020 | $600.36M | +29.4% |
| Q1 FY2020 | Mar 31, 2020 | $346.17M | -28.1% |
| Q4 FY2019 | Dec 31, 2019 | $401.83M | +75.6% |
| Q3 FY2019 | Sep 30, 2019 | $446.47M | +216.0% |
| Q2 FY2019 | Jun 30, 2019 | $464.00M | +1334.5% |
| Q1 FY2019 | Mar 31, 2019 | $481.22M | +507.8% |
| Q4 FY2018 | Dec 31, 2018 | $228.86M | +72553.3% |
| Q3 FY2018 | Sep 30, 2018 | $141.27M | +235345.0% |
| Q2 FY2018 | Jun 30, 2018 | $32.35M | – |
| Q1 FY2018 | Mar 31, 2018 | $79.18M | – |
| Q4 FY2017 | Dec 31, 2017 | $315.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $60.00K | – |
See a number that looks wrong?